Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.


B-cell lymphoproliferative disorders are a continuum from benign cutaneous lymphoid hyperplasia (CLH) or "pseudolymphoma" to primary cutaneous B-cell lymphoma (PCBCL). Historically, CLH was treated with a combination of antibiotics, topical or intralesional corticosteroids, and/or localized radiotherapy. Rituximab, a monoclonal antibody that targets the CD20 marker on B cells, is an effective and well-reported treatment for PCBCL. We review the pathogenesis and current treatments of B-cell lymphoproliferative disorders and assess the role of rituximab for potential therapy in the setting of refractory CLH. We describe a case of CLH that was treated with intralesional rituximab. The patient had notable clinical improvement over the treatment period with rituximab. Because of some persistent and recurrent erythematous areas, topical tacrolimus was initiated, with significant clinical improvement. There were no reported side effects. Management of CLH with intralesional rituximab has been described. The treatment presented in this report substantiates rituximab as a reasonable therapeutic option for refractory CLH after failure of several other widely accepted treatments. Treatment with intralesional rituximab should be reserved for patients with documented CD20(+) lesions.

DOI: 10.1016/j.clml.2011.03.017

Cite this paper

@article{Martin2011TreatmentOC, title={Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.}, author={Stephanie J Martin and Madeleine Duvic}, journal={Clinical lymphoma, myeloma & leukemia}, year={2011}, volume={11 3}, pages={286-8} }